238 related articles for article (PubMed ID: 21284830)
1. First pharmacophore model of CCR3 receptor antagonists and its homology model-assisted, stepwise virtual screening.
Jain V; Saravanan P; Arvind A; Mohan CG
Chem Biol Drug Des; 2011 May; 77(5):373-87. PubMed ID: 21284830
[TBL] [Abstract][Full Text] [Related]
2. Small molecule antagonists for chemokine CCR3 receptors.
Willems LI; Ijzerman AP
Med Res Rev; 2010 Sep; 30(5):778-817. PubMed ID: 19967721
[TBL] [Abstract][Full Text] [Related]
3. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW
Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418
[TBL] [Abstract][Full Text] [Related]
4. Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets?
Bissantz C; Bernard P; Hibert M; Rognan D
Proteins; 2003 Jan; 50(1):5-25. PubMed ID: 12471595
[TBL] [Abstract][Full Text] [Related]
5. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.
Axe FU; Bembenek SD; Szalma S
J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore identification and virtual screening for methionyl-tRNA synthetase inhibitors.
Bharatham N; Bharatham K; Lee KW
J Mol Graph Model; 2007 Mar; 25(6):813-23. PubMed ID: 16996282
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening.
Cavasotto CN; Orry AJ; Murgolo NJ; Czarniecki MF; Kocsi SA; Hawes BE; O'Neill KA; Hine H; Burton MS; Voigt JH; Abagyan RA; Bayne ML; Monsma FJ
J Med Chem; 2008 Feb; 51(3):581-8. PubMed ID: 18198821
[TBL] [Abstract][Full Text] [Related]
8. Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model.
Lescot E; Sopkova-de Oliveira Santos J; Colloc'h N; Rodrigo J; Milazzo-Segalas I; Bureau R; Rault S
Proteins; 2008 Oct; 73(1):173-84. PubMed ID: 18409194
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
[TBL] [Abstract][Full Text] [Related]
10. Computational investigation of interactions between human H2 receptor and its agonists.
Sun X; Li Y; Li W; Xu Z; Tang Y
J Mol Graph Model; 2011 Feb; 29(5):693-701. PubMed ID: 21212009
[TBL] [Abstract][Full Text] [Related]
11. A common feature-based 3D-pharmacophore model generation and virtual screening: identification of potential PfDHFR inhibitors.
Adane L; Bharatam PV; Sharma V
J Enzyme Inhib Med Chem; 2010 Oct; 25(5):635-45. PubMed ID: 19995305
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophore mapping and in silico screening to identify new potent leads for A(2A) adenosine receptor as antagonists.
Mustyala KK; Chitturi AR; Naikal James PS; Vuruputuri U
J Recept Signal Transduct Res; 2012 Apr; 32(2):102-13. PubMed ID: 22384789
[TBL] [Abstract][Full Text] [Related]
13. Molecular docking study of A(3) adenosine receptor antagonists and pharmacophore-based drug design.
Wei J; Li H; Qu W; Gao Q
Neurochem Int; 2009 Dec; 55(7):637-42. PubMed ID: 19540293
[TBL] [Abstract][Full Text] [Related]
14. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
[TBL] [Abstract][Full Text] [Related]
15. Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.
Krovat EM; Langer T
J Med Chem; 2003 Feb; 46(5):716-26. PubMed ID: 12593652
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potential integrin VLA-4 antagonists using pharmacophore modeling, virtual screening and molecular docking studies.
Thangapandian S; John S; Sakkiah S; Lee KW
Chem Biol Drug Des; 2011 Aug; 78(2):289-300. PubMed ID: 21507205
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.
Aparoy P; Kumar Reddy K; Kalangi SK; Chandramohan Reddy T; Reddanna P
Bioorg Med Chem Lett; 2010 Feb; 20(3):1013-8. PubMed ID: 20045317
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationships of N-{1-[(6-fluoro-2-naphthyl)methyl]piperidin-4-yl}benzamide derivatives as novel CCR3 antagonists.
Sato I; Morihira K; Inami H; Kubota H; Morokata T; Suzuki K; Hamada N; Iura Y; Nitta A; Imaoka T; Takahashi T; Takeuchi M; Ohta M; Tsukamoto S
Bioorg Med Chem; 2008 Jan; 16(1):144-56. PubMed ID: 17951061
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure.
Park H; Chi O; Kim J; Hong S
J Chem Inf Model; 2011 Nov; 51(11):2986-93. PubMed ID: 22017333
[TBL] [Abstract][Full Text] [Related]
20. Pharmacophore based virtual screening, molecular docking studies to design potent heat shock protein 90 inhibitors.
Sakkiah S; Thangapandian S; John S; Lee KW
Eur J Med Chem; 2011 Jul; 46(7):2937-47. PubMed ID: 21531051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
